Robert Edfors1,2, Tomas Jernberg1, Christian Lewinter3, Mai Blöndal4,5, Jaan Eha4,5, Piret Lõiveke5,6, Toomas Marandi5,6,7, Tiia Ainla5,6, Aet Saar6, Gudrun Veldre5,8, Tamas Ferenci9,10, Péter Andréka11, András Jánosi11, Jarle Jortveit12, Sigrun Halvorsen13. 1. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Morbygardsvagen 5, 1882 57 Stockholm, Sweden. 2. Bayer AB, Berzelius vag 35, 171 65 Stockholm, Sweden. 3. Heart and Vascular Theme, Section of Cardiology, Karolinska University Hospital, Eugeniavagen 23, 17165 Stockholm, Sweden. 4. Heart Clinic, Tartu University Hospital, 8 L. Puusepa Street, 50406 Tartu, Estonia. 5. Department of Cardiology, University of Tartu, 8 L. Puusepa Street, 50406 Tartu, Estonia. 6. Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Street, 13419 Tallinn, Estonia. 7. Quality Department, North Estonia Medical Centre, 19 J. Sütiste Street, 13419 Tallinn, Estonia. 8. Estonian Myocardial Infarction Registry, Tartu University Hospital, 8 L. Puusepa Street, 50406 Tartu, Estonia. 9. John von Neumann Faculty of Informatics, Institute of Biomatics, Obuda University, Bécsi út 96/b, 1034 Budapest, Hungary. 10. Department of Statistics, Corvinus University of Budapest, Keleti Károly Street 5-7, 1024 Budapest, Hungary. 11. Gottsegen György National Institute of Cardiology, Hungarian Myocardial Infarction Registry, Haller str 29, 096 Budapest Hungary, Hungary. 12. Department of Cardiology, Sorlandet Hospital, Box 783, Stoa, 4809 Arendal, Norway. 13. Department of Cardiology, Oslo University Hospital Ulleval, Oslo and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
Abstract
AIMS: To study baseline characteristics, in-hospital managements and mortality of non-ST-elevation myocardial infarction (NSTEMI) patients in different European countries. METHODS AND RESULTS: NSTEMI patients enrolled in the national myocardial infarction (MI) registries [EMIR; n = 5817 (Estonia), HUMIR; n = 30 787 (Hungary), NORMI; n = 33 054 (Norway), and SWEDEHEART; n = 49 533 (Sweden)] from 2014 to 2017 were included and presented as aggregated data. The median age at admission ranged from 70 to 75 years. Current smoking status was numerically higher in Norway (24%), Estonia (22%), and Hungary (19%), as compared to Sweden (17%). Patients in Hungary had a high rate of diabetes mellitus (37%) and hypertension (84%). The proportion of performed coronary angiographies (58% vs. 75%) and percutaneous coronary interventions (38% vs. 56%), differed most between Norway and Hungary. Prescription of dual antiplatelet therapy at hospital discharge ranged from 60% (Estonia) to 81% (Hungary). In-hospital death ranged from 3.5% (Sweden) to 9% (Estonia). The crude mortality rate at 1 month was 12% in Norway and 5% in Sweden (5%), whereas the 1-year mortality rates were similar (20-23%) in Hungary, Estonia, and Norway and 15% in Sweden. CONCLUSION: Cross-comparisons of four national European MI registries provide important data on differences in risk factors and treatment regiments that may explain some of the observed differences in death rates. A unified European continuous MI registry could be an option to better understand how implementation of guideline-recommended therapy can be used to reduce the burden of cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To study baseline characteristics, in-hospital managements and mortality of non-ST-elevation myocardial infarction (NSTEMI) patients in different European countries. METHODS AND RESULTS: NSTEMI patients enrolled in the national myocardial infarction (MI) registries [EMIR; n = 5817 (Estonia), HUMIR; n = 30 787 (Hungary), NORMI; n = 33 054 (Norway), and SWEDEHEART; n = 49 533 (Sweden)] from 2014 to 2017 were included and presented as aggregated data. The median age at admission ranged from 70 to 75 years. Current smoking status was numerically higher in Norway (24%), Estonia (22%), and Hungary (19%), as compared to Sweden (17%). Patients in Hungary had a high rate of diabetes mellitus (37%) and hypertension (84%). The proportion of performed coronary angiographies (58% vs. 75%) and percutaneous coronary interventions (38% vs. 56%), differed most between Norway and Hungary. Prescription of dual antiplatelet therapy at hospital discharge ranged from 60% (Estonia) to 81% (Hungary). In-hospital death ranged from 3.5% (Sweden) to 9% (Estonia). The crude mortality rate at 1 month was 12% in Norway and 5% in Sweden (5%), whereas the 1-year mortality rates were similar (20-23%) in Hungary, Estonia, and Norway and 15% in Sweden. CONCLUSION: Cross-comparisons of four national European MI registries provide important data on differences in risk factors and treatment regiments that may explain some of the observed differences in death rates. A unified European continuous MI registry could be an option to better understand how implementation of guideline-recommended therapy can be used to reduce the burden of cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Petr Toušek; David Bauer; Marek Neuberg; Markéta Nováčková; Petr Mašek; Petr Tu Ma; Viktor Kočka; Zuzana Moťovská; Petr Widimský Journal: Eur Heart J Suppl Date: 2022-03-30 Impact factor: 1.624